Cargando…
Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer
BACKGROUND: The International Duration Evaluation of Adjuvant chemotherapy project investigated whether a shorter duration of oxaliplatin-based adjuvant chemotherapy was as effective as 6 months of identical chemotherapy for resected stage III colon cancer. As part of this project, we report safety...
Autores principales: | Kotaka, Masahito, Yamanaka, Takeharu, Yoshino, Takayuki, Manaka, Dai, Eto, Tetsuya, Hasegawa, Junichi, Takagane, Akinori, Nakamura, Masato, Kato, Takeshi, Munemoto, Yoshinori, Nakamura, Fumitaka, Bando, Hiroyuki, Taniguchi, Hiroki, Gamoh, Makio, Shiozawa, Manabu, Saji, Shigetoyo, Maehara, Yoshihiko, Mizushima, Tsunekazu, Ohtsu, Atsushi, Mori, Masaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922566/ https://www.ncbi.nlm.nih.gov/pubmed/29713499 http://dx.doi.org/10.1136/esmoopen-2018-000354 |
Ejemplares similares
-
Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial
por: Yoshino, Takayuki, et al.
Publicado: (2019) -
Poor association between dihydropyrimidine dehydrogenase (
DPYD
) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022) -
Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study
por: Tomita, Naohiro, et al.
Publicado: (2019) -
JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer
por: Yoshino, Takayuki, et al.
Publicado: (2019) -
Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)
por: Kotaka, Masahito, et al.
Publicado: (2015)